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Abstract
Zoonoses are infectious diseases transmitted directly or indirectly between animals and humans. Several important
zoonotic pathogens colonize farm animals asymptomatically, which may lead to contamination of the food chain
and public health hazards. Moreover, routine sampling of carcasses at retail by government authorities over the
past 20 years suggests the prevalence of antibiotic resistance in foodborne pathogens has increased. If this
continues, antibiotics may be ineffective against such pathogens in the future and alternative approaches, such as
phage therapy, may be necessary. Intensive livestock farming is the only realistic way of meeting the demand for
meat from an increasing global population and growth in middle class consumers in developing countries,
particularly in Asia. This review elaborates on the use of phages to control zoonotic pathogens in intensively-reared
livestock (poultry and pigs).
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Background
Poultry and pig intensive farming
A significant increase in meat production will be re-
quired over the coming decades in order to meet de-
mand from a growing global population and greater
income and dietary choice in developing countries [1].
So far, much of this demand has been met by intensive
livestock farming, particularly poultry and pigs. Unfortu-
nately, such production systems can facilitate disease
transmission as these animals often have low genetic di-
versity and are reared in large and dense populations [2].
The Food and Agricultural Organization (FAO) reported
that between 1961 and 2016, world poultry meat pro-
duction increased from 9 to 120 million tonnes, and egg
production grew from 15 to 81 million tonnes [3]. The
most recent FAO meat market review report estimated
that poultry and pig meat production was 123.9 and
120.5 million tonnes respectively in 2018 [4]. In many
parts of the world, antimicrobials are used in intensive
farming for growth promotion, disease prevention, or
therapy which may select for populations of antibiotic-
resistant pathogens [2]. In the USA in 2012, animals
consumed 70% of medically important antibiotics (8.9
tons) [5]. In China, the livestock industry will use up to
30% of global antimicrobial production by 2030 [6]. The
emergence of antimicrobial resistance in bacterial patho-
gens will inevitably result in treatment failure, increased
pathogen transmission and concomitant production
losses [7].
Bacterial zoonoses and intensively-reared livestock
The most common zoonotic bacterial pathogens associ-
ated with poultry and pigs are Salmonella spp., E. coli,
Campylobacter spp., Clostridium spp. and Listeria spp. [8,
9]. The most recent European Food Safety Authority
(EFSA) report states that these pathogens are often resist-
ant to several antibiotics [9, 10]. In the EU, the official data
about zoonotic and indicator bacteria from humans, ani-
mals and food show high proportions (28.6% out of more
than 8000) of human Salmonella isolates were resistant to
three or more antimicrobials [10]. Additionally, 34.9% of
indicator isolates of E. coli from fattening pigs were multi-
drug resistant [10]. The pipeline for developing new anti-
biotics to counter this resistance is running dangerously
low on new candidate molecules [11] and alternative ap-
proaches are urgently needed. One option is the use of
lytic bacteriophages to combat bacterial diseases in live-
stock [12]. A review sponsored by the UK Department of
Health and the Wellcome Trust reported that, of the top
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10 most promising alternatives to antibiotics, three were
based on using bacteriophages or their components [13].
Bacteriophages were discovered in the early twentieth
century by Twort (1915) and d’Herelle (1917) while
working independently in the UK and France, respect-
ively [14]. D’Herelle [15] first tested phage therapy in an-
imals, with the successful treatment of fowl typhoid in
chickens (95–100% survival of phage-treated birds com-
pared with 0–25% for untreated controls). Pyle [16] re-
ported using phage to treat chickens with a systemic
Salmonella infection caused by Salmonella enterica sero-
type Pullorum. While the phage demonstrated marked
bacteriolysis in vitro; when used in vivo they did not re-
duce mortality or have much therapeutic effect. Follow-
ing the discovery of antibiotics in the 1920s, little work
was done in the West using phage to treat infections of
livestock until Williams Smith’s pioneering studies of
the 1980s. For a more extensive review of the history of
phage use in agriculture and animals, see the review by
Sulakvelidze and Barrow [17]. The following sections
summarise findings from more recent phage therapy
studies in poultry and pigs.
Main text
Salmonellosis
Salmonella is a common target for phage therapy be-
cause it causes disease in a wide range of endothermic
animals as well as humans and causes significant pro-
duction losses in livestock. Some Salmonella serotypes
(e.g. S. enterica serotype Typhi) are known as ‘host-re-
stricted’ because they produce a severe, systemic,
typhoid-like illness in a single host (or small number of
related hosts). However, phage therapy has mainly fo-
cussed on ‘non-host-restricted’ serotypes (principally
Enteritidis and Typhimurium) which usually result in a
less severe gastrointestinal infection across a much
broader range of species and lead to most foodborne
bacterial infections in developed countries [17, 18].
Phage therapy has been used to control Salmonella in
chickens with varying degrees of success. Sklar et al.
used phages in a broiler chick model to demonstrate
that Salmonella colonization of the cecum could be sig-
nificantly reduced by almost 1 log10 Colony Forming
Units (CFU)/g gut contents over 14-days by administer-
ing a cocktail of four phages in feed (109 Plaque Form-
ing Units (PFU)/g) [19]. Additionally, phage treatment
appeared to reduce secondary infection signs in the
birds as only three out of 10 animals in the phage-
treated group showed mild inflammation on the air sacs
while 8 out of 10 birds in the untreated control group
showed signs of airsacculitis. Fiorentin et al. demon-
strated that a single oral dose of three phages each at
1011 PFU could reduce S. Enteritidis colonisation of
broiler chickens by 3.5 log10 CFU/g in the broiler
chicken caecum when exposed to 7-days-old seeder
chicks infected with 108 CFU of S. Enteritidis [20].
Atterbury et al. [21] selected three lytic phage (isolated
from poultry farms and wastewater in the UK) with a
broad host range against S. Enteritidis, S. Hadar and S.
Typhimurium. A 9.0 log10 PFU suspension of each
phage was used to treat 36-day-old Ross broiler chickens
which had been separately infected with the three differ-
ent serotypes. All of the phages tested reduced Salmon-
ella colonisation of the ceca, although only S. Enteritidis
and S. Typhimurium were reduced significantly; by ap-
proximately 2.19–2.52 log10 CFU/g compared with the
controls. Bacteriophage-insensitive mutants (BIMs) were
recovered from phage-treated animals. However, this
phage-resistant phenotype was not maintained in vitro
following successive subculturing, nor in vivo when
BIMs were introduced into a new group of birds in the
absence of phage selective pressure.
Lim et al. demonstrated how phage could be used to
prevent horizontal infection by Salmonella Enteritidis in
a commercial layer chick seeder model [22]. Groups of
1-day-old chicks were challenged with 5 × 1011 CFU of
Salmonella Enteritidis and for the next 21 days cohabi-
tated with uninfected contact chicks while being treated
in three independent groups with one of three titres
(105,107 or 109 PFU/g) of bacteriophage prepared as a
feed additive. All the treatments significantly (P < 0.05)
reduced the intestinal colonization by up to 1 log10
CFU/g at the end of the 21 days, with 70% of the contact
chickens treated with the highest phage titre having no
detectable Salmonella Enteritidis colonization. Borie
et al. [23] administered a combination of three Salmon-
ella-specific phages (108 PFU/mL/dose) via coarse spray
or drinking water on 10-day-old chicks 24 h before the
experimental challenge with 9.6 × 105 CFU S. Enteritidis.
Phage delivery both by coarse spray and drinking water
significantly reduced the mean intestinal S. Enteritidis
counts by up to 1.6 log10 CFU/mL .
Ahmadi et al. [24] determined the ability of phages to
reduce S. Enteritidis in the ceca of Japanese quails. Phage
‘PSE’ was administered to groups of 8-day-old quail by
oral gavage either prophylactically (105 PFU) three days
before challenge with 108 CFU S. Enteritidis; or thera-
peutically immediately after S. Enteritidis challenge.
Prophylactic administration reduced the detection of
Salmonella in the ceca to 33.3 and 20%, 24 h and 7 days
after PSE administration, respectively, while in the in-
fected control group all birds tested positive for S. Enteri-
tidis in the cecal tonsils. No such reduction was recorded
in the birds treated therapeutically. In a further experi-
ment, groups of 1-day-old quail were treated with 108
PFU of phage PSE daily for six days, either by oral gavage
or vent lip. On day four, these birds were challenged with
108 CFU of S. Enteritidis. Salmonella was detected in the
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ceca of birds treated orally with phage PSE 6 h following
Salmonella challenge, but not subsequently up to 35 days
post challenge. Some birds (up to 2 out of 8) treated with
phage PSE via the vent lip periodically tested positive for
S. Enteritidis throughout the study period, but the major-
ity remained free of S. Enteritidis.
Besides the application in poultry, the effect of phage
cocktails against Salmonella in pigs has also been dem-
onstrated. Wall et al. [25] administered 5 × 109 CFU of
S. Typhimurium γ4232 and, simultaneously, microen-
capsulated alginate beads containing 5 × 109 PFU of 16
phages mixed as cocktail, to 3 to 4 week old pigs by
gavage. The authors reported a 2 to 3 log10 CFU/g re-
duction in the Salmonella counts in the ileum, caecum
and tonsils. In a different experimental design, market-
weight pigs were challenged with 5 × 109 CFU S. Typhi-
murium orally and then treated with 1010 PFU of mi-
croencapsulated phage cocktail 48 h later (administered
orally three times, with 2 h interval between doses)
followed by comingling with Salmonella-infected seeder
pigs. Salmonella average cecal counts in the phage-
treated pigs were significantly reduced by 1.4 log10
CFU/mL compared with untreated controls.
Saez et al. [26] administered a bacteriophage cocktail as
a microencapsulated feed additive and demonstrated it
can be an effective and practical way of reducing Salmon-
ella colonization and shedding in pigs. The experimental
design comprised 21 pigs randomly separated into three
groups. Group 1 was given a feed additive containing a
microencapsulated phage cocktail (5 × 1011 PFU per day)
for 5 days before being orally challenged with 5mL of 109
CFU/mL Salmonella Typhimurium. Group 2 was given
60mL of the phage cocktail (5 × 1011 PFU) every 2 h after
the challenge, during a total of 6 h. Group 3 received no
phage treatment, and all groups were orally challenged on
the fifth day with 5mL of 109 CFU/mL S. Typhimurium
bacterial suspension. The results showed lower faecal
shedding of S. Typhimurium at 2 h post challenge (group
1 = 38.1%, group 2 = 71.4%, group 3 = 71.4%, P < 0.05) and
4 h post challenge (group 1 = 42.9%, group 2 = 81.1%,
group 3 = 85.7%, P < 0.05) when the phage cocktail was
administered as a feed additive. Additionally, S. Typhimur-
ium counts in ileal and cecal contents were 1 log10 CFU/g
lower in the phage-treated feed additive group compared
with the control group.
Seo et al. [27] determined the therapeutic potential of
a bacteriophage cocktail which was able to kill 34 refer-
ence strains and 99 isolates (107 tested) of S. Typhimur-
ium. Groups of four-week-old pigs were given 5 mL of a
phage cocktail at 109 PFU/mL until the end of the study
(15 days) and at day 7 were challenged with 10 mL of S.
Typhimurium (ATCC140828) at 108 CFU/mL. No Sal-
monella shedding was detected in the fecal samples 7
days post infection in the phage treated group compared
with a mean colonisation of 1.0 log10 CFU/mL for the
untreated control group.
The administration of Salmonella phages orally ex-
poses them to potentially hostile conditions, such as low
pH of the stomach/gizzard and the activities of bile and
enzymes in the duodenum, which may impact bacterio-
phage viability. Various approaches have been used to
mitigate against the potential damage which these condi-
tions may cause, including concomitant administration
of antacid [21], microencapsulation with chitosan/algin-
ate [28] microencapsulation with alginate [29], microen-
capsulation with antacid/alginate [30] and liposome
nanoencapsulation [31].
Colibacillosis
Pathogenic strains of Escherichia coli in poultry are the
causal agent of colibacillosis which is responsible for
considerable mortality in poultry. E. coli colonization of
the avian respiratory tract may progress down to the air
sacs causing septicaemia and ultimately death [32]. In
broiler chickens, Huff et al. [33] demonstrated the effi-
cacy of administering a high titre mixture of phage by
spray to reduce colibacillosis-associated mortality. In this
model, high titres of two phage (SPR02, 2.6 × 108 PFU/
mL and DAF6, 2.35 × 109 PFU/mL) were administered
by spray at day 7, followed by challenge with a patho-
genic E. coli injected directly into the thoracic air sac
(5.6 × 104 CFU) at day 7, 8 or 10. Phage treatment re-
sulted in a significant reduction in mortality which was
most pronounced when the phage were administered at
the same time as the bacterial challenge (30% mortality
vs 60% mortality for untreated control birds). Note-
worthy, one experimental group of birds was found to
be already infected with E. coli which was susceptible to
lysis by phage SPR02. The authors suspected that this
was due to a naturally-occurring infection, though this
was not confirmed. These birds had a slight lower hatch
weight, and a significantly higher mortality in the un-
treated control group (20%) and buffer spray control
group (27%) compared with the phage treated group
(3%). This suggested that phage administration might
have provided therapeutic treatment for the pre-existing
colibacillosis.
Huff et al. [34] again used phage SPR02 in a different
phage therapy model. Groups of ten 3-day-old chicks
were challenged with 103 to 104 CFU of E. coli by direct
injection into the air sacs. One group was administered
phage (103 or 106 PFU) simultaneously with the E. coli,
the second group was administered phage via drinking
water. Administration of phage via drinking water had
no protective effect, whereas simultaneous injection was
associated with a reduced mortality (25% or 5% for birds
treated with 103 and 106 PFU respectively). This com-
pared favourably with 80% mortality recorded for the
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untreated control group. However, the mixing of phage
and host during administration is likely to produce artifi-
cially positive results, as the phage will have the oppor-
tunity to infect and replicate within the bacteria before
they have a chance to establish an infection; effectively
reducing the challenge.
Huff et al. [35] again used phages SPR02 and DAF6 to
treat colibacillosis, this time by aerosol spray or intra-
muscular injection. The challenge used 5.96 × 104 CFU
of E. coli injected in the left thoracic air sac of 7-day-old
chicks. The phage treatment using the aerosol spray
(7.65 × 108 and 2.83 × 109 PFU/mL, DAF6 and SPR02,
respectively) provided significant protection to the birds
as shown by the low mortality of the treated group
(20%) when compared to the control group (50%). How-
ever, if phage treatment was delayed by 24 or 48 h after
bacterial challenge, no therapeutic benefit was observed.
Conversely, birds treated with a combination of phages
(1.88 × 109 and 6.35 × 108 PFU/mL of DAF6 and SPR02,
respectively) by intramuscular injection had a signifi-
cantly lower mortality (≤ 20%) compared with the con-
trol group (53%) whether phage were administered
immediately or up to 48 h after bacterial challenge.
These results reinforce the notion that the administra-
tion route plays a fundamental part in the phage therapy
outcome, as the best results appear to be achieved by
injecting phage into the birds, which given the nature of
poultry farming in unlikely to offer a practical solution
to colibacillosis.
Huff et al. [36] evaluated the potential synergy of anti-
biotics and phage treatment for colibacillosis. Groups of
ten seven-days-old chicks were challenged with 6 × 104
CFU of E. coli injected into the left thoracic air sac. This
was followed immediately by injection of one of two
phages directly into the thigh muscle (3.7 × 109 and
9.3 × 109 PFU per mL of phages DAF6 or SPR02, re-
spectively). Enrofloxacin was introduced into the birds’
drinking water at 50 ppm for 7 consecutive days, starting
immediately after E. coli challenge. High mortality (68%)
was recorded for the untreated control group. This com-
pared with 15% mortality in the phage-treated group, 3%
mortality in the enrofloxacin-treated group and 0% for
birds treated with both phage and antibiotic. This led
the authors to suggests the occurrence of synergy be-
tween both therapeutic agents when used in combin-
ation with improved efficacy.
Oliveira et al. [37] tested phage delivery using a fine
drop scatter spray in experimentally and naturally in-
fected chickens. Groups of twelve 10-week-old Rhode Is-
land Red chickens were challenged with 1 × 108 CFU of
avian pathogenic E. coli H839E, by injection in the left
thoracic air sac. The phage-treated group was given a
suspension of 1.5 × 109 PFU phi F78E, orally and by
spray. The results showed a significantly (P < 0.05) lower
pathology score (≈2.5), morbidity (≈60%) and mortality
(≈45%) in the phage-treated group when compared to
the untreated control pathology (≈4), morbidity (≈100%)
and mortality (≈75%) scores. Moreover, the average
mortality was 25.0% lower, the average morbidity 41.7%
lower, and the lesions found in carcasses were also less
severe in the phage-treated group, when compared with
the untreated controls.
El-Gohary et al. [38] tested the spray delivery of phages
onto litter as a means to reduce colibacillosis. The surface
of the litter in 3.9 m2 pens was sprayed with 200mL of a
2.8 × 108 CFU/mL of a culture of pathogenic E. coli. For
phage-treated groups, the pens were immediately sprayed
with 200mL of a 8 × 108 PFU/mL suspension of phage
SPR02. The mortality of the control and the phage-treated
groups was 25 and 5%, respectively. The authors suggest
that sanitising the environment with phages reduces the
level of the target pathogen to below the infectious dose,
hindering the onset of bacterial diseases, and claim it is a
practical and efficacious way to prevent colibacillosis in
broiler chickens. However, the metabolic state of in vitro
cultured bacteria, such as those sprayed on litter, may dif-
fer substantially from sub-lethally injured cells which may
be found naturally in the farm environment. As such, it
may be difficult to repeat these results in a real poultry
farm scenario.
Besides respiratory infections in poultry, colibacillosis in
a meningitis and septicaemia model were addressed in
poultry with a phage therapy approach [39]. The experi-
mental design used 3-week-old Rhode Island Red chickens
infected with E. coli H247 K1+ via intramuscular or intra-
cranial administration, followed by an intramuscular injec-
tion of phage R at 104 or 106 PFU. Mortality in the phage
treated groups was zero, compared with 100% in the un-
treated control group. None of the birds treated with
phage exhibited clinical signs of infection. Moreover,
delaying phage treatment until clinical signs of disease
were evident still led to considerable protection as all 10
untreated control birds died compared with 3 out of 10
for the phage-treated group. Prophylactic administration
of phage up to two days before bacterial challenge was
also effective in reducing mortality to 1 out of 9 in the
phage treated group compared with 4 out of 9 in the con-
trol group. Phage R was able to multiply in the blood and
penetrate the blood-brain barrier. Together, this data sup-
ports the idea that even acute infections might be amen-
able to phage treatment.
Pioneering work in phage therapy addressing colibacil-
losis in pigs (and also mice, cattle and sheep) was per-
formed in the 1980s by Smith and Huggins [40–42]. In
one study, diarrhoea was induced in piglets by giving
them 3 × 108 CFU of pathogenic E. coli O20:K101 987P
to seven piglets and 13-16 h later they were treated by
oral administration of a mixture (1010 PFU) of two
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phages (P433/1 and P433/2) or a single phage (P433/1).
Symptoms of disease in phage-treated piglets ceased 18-
22 h later, while the challenged untreated piglets were
severely ill, markedly dehydrated, ataxic, mentally con-
fused and if they had not been fed by stomach tube, the
authors claim the whole group of seven piglets would
have died [41].
Jamalludeen et al. [43] showed a beneficial effect of
phages on weaned pigs infected with an enterotoxigenic
E. coli O149:H10:F4. The pigs were inoculated orally by
syringe with 1010 CFU of E. coli, followed by treatment
with six phages (GJ1-GJ7) either individually or com-
bined in a dose of 109 PFU of each phage. These phages
were administered either prophylactically (15 min after
challenge) or therapeutically (24 h after challenge). The
antibiotic florfenicol was used prior to the bacterial chal-
lenge in an attempt to enhance E. coli colonization. The
prophylactic use of the six phages individually signifi-
cantly reduced the duration and severity of the diarrhoea
as shown by the clinical symptom score of < 4 when
compared with ≈10 from the challenged control. More-
over, the therapeutic administration of a two phage
cocktail significantly reduced the symptoms, the devel-
opment of diarrhoea and the shedding of the pathogenic
E. coli without changes to the commensal E.coli numbers
[43]. The usage of bacteriophages as an in-feed additive
for pigs, administered prophylactically, was regarded as
safe as it had no adverse immunological effects, and may
also result in improved weight gain [44–47].
Campylobacteriosis
Campylobacter spp. is the most significant cause of
acute bacterial food borne disease in the EU [48]. Ap-
proximately 95% of all reported cases result from infec-
tion with one species, C. jejuni. Campylobacter is highly
adapted to the colonisation of the avian gut and has a
relatively low infectious dose for humans (thought to be
approximately 500 cells [49]). There is a host immune
response, manifest by the sIgA antibodies titre, however
it has little to no effect on the level of colonization of C.
jejuni in broilers [50]. High counts of Campylobacter
bacteria on broiler caeca may result in carcass contamin-
ation at the abattoir. It has been calculated that a reduc-
tion of Campylobacter counts on carcasses by 2 log10
may result in a 30-fold decrease in human campylobac-
teriosis [51]. The antibiotic resistance profile of 486
campylobacters isolated from retail chickens by the UK
Food Standards Agency from 2016 to 17 found resist-
ance to ciprofloxacin (251), tetracycline (322), nalidixic
acid (247), streptomycin (18) and erythromycin (2). Mul-
tidrug resistance to three or more antibiotics was re-
corded for 17 isolates [52]. These results stress the need
for an effective solution to deal with contamination of
poultry carcasses with Campylobacter.
Wagenaar et al. [53] determined whether a phage prep-
aration administered by oral gavage (from day 7 to 16)
could protect 10-day-old Ross broiler chicks or adult
chickens from a challenge with C. jejuni (105 CFU/mL on
day 10). The phage preparation did not show any protect-
ive effect in the birds, however, when administered after
the bacterial challenge, a 3 log10 CFU/g reduction in the
counts of C. jejuni was observed in the caeca of phage-
treated birds. Loc-Carrillo et al. [54] selected two phages
(CP8 and CP34) from a panel of 53 isolated from chicken
faeces to use as candidates to reduce Campylobacter in
chickens. The phages were selected on the basis of
favourable in vitro replication kinetics and a broad host
range. Ross broiler chickens were experimentally infected
with C. jejuni isolates HPC5 and GIIC8 at various doses
(from 2.7 to 7.8 log10 CFU) by oral gavage at 18 to 20 days
of age. A single phage treatment (5–9 log10 PFU) was ad-
ministered at 25 days of age by oral gavage. C. jejuni
counts in the upper intestine and ceca of phage-treated
birds were reduced by between 0.5 and 5 log10 CFU/g
when phages were applied at ≥107 PFU. Phage-resistant C.
jejuni isolates were recovered from phage-treated birds
(4%) but this was markedly lower than recovery of resist-
ant isolates from in vitro studies (11%). The authors sug-
gested that, in the absence of phage selective pressure,
phage-resistant mutants may colonise the chicken gut less
effectively. This interpretation is supported by the authors’
observation that when phage-resistant isolates are used to
challenge birds in the absence of phage, 97% of campylo-
bacters reverted to a phage-sensitive phenotype [54]. In a
previous study, the same group showed that in 90 UK
broiler flocks, counts of C. jejuni in the presence of natur-
ally occurring bacteriophages were lower when compared
to samples where phage could not be detected (5.1 vs 6.9
log10 CFU/g respectively) [55].
Lytic phages that infect Campylobacter have been cat-
egorized into three groups (I to III) based on the struc-
ture, genome size and receptor used to infect the host
[56]; and phages from group II and II apparently use
multiple host cell receptors for binding [57–59]. El-
Shibiny et al. [60] recorded a 2 log10 CFU/g reduction in
caecal counts of Campylobacter HPC5 48 h after admin-
istering a single 107 PFU dose of group II bacteriophage
CP220. The incidence of phage resistance in colonized
chickens after phage treatment was shown to be residual,
only around 2% of the population [60]. More recently,
Hammerl et al. [61] used a combined treatment of group
II and III phages. Groups of 20-day-old male Vrolix
chicks were inoculated with 109 CFU of C. jejuni. After
7 days the infected birds were administered a phage sus-
pension of 5 × 108 PFU of CP14 (group III), CP81 (group
III) or CP68 (group II) either alone or combined. At 31
days of age the experimental birds were euthanised and
the C. jejuni counts in caeca revealed a 1 log10 CFU/g
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reduction in cecal colonisation when treated with CP14
alone, compared with the control group. The addition of
CP81 to CP14 did not improve this reduction. However,
a 3 log10 CFU/g reduction was recorded when treatment
with CP14 was followed by CP68 the next day. The au-
thors claim the different host receptors used by group II
and III phages are the underlying reason for both the
significant reduction in Campylobacter counts and also
for the lower levels of resistant isolates obtained when
using a mixture group II and III phages (3%) when com-
pared to the single CP14 phage (4%) or two phages from
the same group III (8%).
As Campylobacter colonizes the caeca in birds, and
does not appear to be very invasive, phage are usually
administered orally. Carvalho et al. [62] found that the
administration of a cocktail of three phages to broiler
chickens by gavage and feed reduced C. jejuni and C.
coli colonisation in broiler chicken faeces by approxi-
mately 2 log10 CFU/g. The authors report the counts of
Campylobacter were maintained 1 log10 CFU lower in
the phage-treated group when compared to the un-
treated control. However, phage resistant isolates re-
covered from faeces (13%) did not show a reduced
ability to colonize the chicken guts or revert to a
phage-sensitive phenotype. More recently, the impact
on the microbiota of broiler chickens infected with
Campyobacter jejuni HPC5 after treatment with a two
phage cocktail was determined [63]. The authors
showed a 2 log10 CFU/g reduction on the Campylobac-
ter counts in cecal content, that in vivo the phages rep-
licate and maintained as a stable population and,
additionally, the infection of C. jejuni by the phages
tested did not affect the microbiota [63].
Clostridiosis
Clostridium perfringens is the causal agent of necrotic en-
teritis, a disease that affects chickens and whose patho-
genesis is incompletely understood. The involvement of
toxins and hydrolases secreted by the bacterium are
thought to be relevant for the virulence and intestinal
colonization by the anaerobic C. perfringens [64]. Add-
itionally, parasites of Eimeria species that colonize the
small intestine, such as Eimeria maxima and Eimeria
acervulina, are known to predispose to necrotic enteritis
by leaking of plasma to the intestinal lumen which pro-
vides a necessary growth substrate for extensive prolifer-
ation of Clostridium perfringens [65]. Phage treatments
have shown some efficacy in reducing the symptoms and
disease progression in chickens. In a study using a total
of 900 birds in various experimental designs, Miller et al.
[66] showed that oral administration of a five phage
cocktail at 105 PFU/mL by oral gavage or drinking water
to experimentally infected Cobb broiler chickens (0 to
42-days old) with C. perfringens resulted in a 92%
reduction in mortality compared with the untreated con-
trol group. Additionally, the authors conclude that in
the 0–42 days period, the specific cocktail used (INT-
401) increased weight gain and feed conversion ratios in
both the phage-in-water group (2.618 ± 0.059 kg) and
phage-in-feed group (2.547 ± 0.059 kg) when compared
to the challenged untreated group (2.296 ± 0.059 kg), and
may be an effective therapy to control the necrotic en-
teritis caused by C. perfringens.
C. perfringens is a Gram-positive bacterium, this im-
plies that the thick peptidoglycan layer is the outmost
barrier exposed to the environment. The phage-
encoded endolysins, enzymes that target and hydrolyse
specific bonds within the peptidoglycan mesh, have
been reported to suffice to achieve bacterial lysis [67].
The usage of purified endolysins from phages that tar-
get C. perfringens is shown as a promising route to re-
duce the colonization or treat the infection by this
pathogen as has been described and subject of review
elsewhere [8, 68–70].
Conclusions
The emergence of antibiotic resistant zoonotic patho-
gens in the food chain is a growing public health prob-
lem worldwide. The lack of new antibiotics coming
onto the market necessitates development of alternative
strategies to deal with these bacteria. Bacteriophages
were used in veterinary applications soon after their
discovery more than a century ago. Whilst the efficacy
of phage therapy varies according to the bacterial target
and complexity and location of the infection site(s),
most recent studies in intensively-reared livestock have
found that these pathogens can be significantly reduced
using phages. This may have a beneficial effect on both
animal and human health, and in some instances may
lead to greater productivity of the industry. Highly-
integrated production systems, found in the poultry
industry for example, are more amenable to phage ther-
apy, as a single company can control all aspects of meat
production before the point of retail sale. Potentially,
this allows the flexibility to introduce phage at various
points, from feed/water or sprays at the farm level to
wash treatments and modified packaging at the abat-
toir. However, in the EU there is no regulatory fra-
mework which would allow such interventions.
Bacteriophage do not fit easily into existing EU regula-
tions regarding the use of food additives or food pro-
cessing aids, which is a significant obstacle.
The emergence of phage-resistant bacterial pathogens
is a threat analogous to the development of antibiotic
resistance. However, resistance to one phage does not
necessarily result in resistance to others, and there ap-
pears to be a fitness cost to resistance in the absence of
phage, at least in some cases. These factors will be
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important when designing phage interventions in the fu-
ture, which may comprise cocktails targeting several dif-
ferent receptors, thus minimising the probability of
resistance emerging. In this context, pathogens which
are more genetically homogeneous, such as Staphylococ-
cus aureus, may be more attractive targets for phage
therapy than genetically diverse hosts such as E. coli, as
fewer phage will be needed to cover the range of clinical
strains circulating in a population at any point in time.
This may also influence the overall phage treatment
strategy as phage deployed prophylactically, rather than
therapeutically, against bacteria such as E. coli are less
likely to result in success than for Staphylococcus aureus.
Also, whilst entry of phage into the wider environment
may be more controllable in intensively-reared livestock,
some release is inevitable and may necessitate the regu-
lar reformulation or cycling of cocktails in order to cir-
cumvent resistance and maintain efficacy. Given the
challenges of meeting the growing demand for meat over
the next century, viable alternatives to antibiotics will be
needed to control disease in increasingly intensifying
production systems. However, like antibiotic chemother-
apy and vaccination, this is unlikely to offer a panacea.
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